Content Includes:
- Epidemiology and Natural History of HCV
- Screening for HCV
- The post-screening process
- Linkage to care and treatment basics
Presenter
Dr. Andrew Hale, MD is an infectious disease physician at the University of Vermont Medical Center and assistant professor at the Larner College of Medicine at UVM in Burlington, VT. Dr. Hale specializes in treating HIV, Hepatitis B and Hepatitis C, and directs various courses at the UVM College of Medicine. His research interests include medical education, HIV, and HCV.
Learning Outcome(s)
At the conclusion of this learning collaborative, (at least 75% of) participants will be able to identify at least three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment.
Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Resources
Wade AJ, Doyle JS, Gane E, et al. Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs. Clinical Infectious Diseases. 2019;70(9):1900-1906.
National Notifiable Diseases Surveillance System (NNDSS). Centers for Disease Control and Prevention (CDC); 2020 https://wwwn.cdc.gov/nndss/conditions/hepatitis-c-acute. Accessed 05/11/2021.
Ly KN, Jiles RB, Teshale EH, Foster MA, Pesano RL, Holmberg SD. Hepatitis C Virus Infection Among Reproductive-Aged Women and Children in the United States, 2006 to 2014. Annals of Internal Medicine. 2017:166(11):775-782.
Centers for Disease Control and Prevention. MMWR 2012: 61, 1:32
Adapted from Pyenson B, et al. Consequences of Hepatitis C Virus (HCV): Costs of a baby boomer Epidemic of Liver Disease. New York, NY Millman, Inc; May 18, 2009.
McGarry LJ et al. Hepatology. 2012;55(5): 1344-1355.
Hepatitis C Prevalence in Vermont: 2006-2015. Vermont Department of Health, National Electronic Disease Surveillance System.; 2020.
Highleyman, L. Hepatitis C Support Project. http://www.hcvadvocate.org/hepatitis/factsheets_pdf/Fibrosis.pdf. Accessed August 18, 2011
Bataller R, Brenner DA. Liver Fibrosis. The Journal of Clinical Investigation. 2005;115(2):209-218.
MedlinePlus. 2012; http://nlm/nih/medlineplus.gov/enxy.article/000280.htm. Accessed August 28, 2012.
Hepatitis C Questions and Answers for Health Professionals. Centers for Disease Control and Prevention (CDC); 2012. Accessed May 8, 2012.
Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: An Inexpensive and Accurate Marker of Fibrosis in HCV Infection. Comparison with Live Biopsy and Fibrotest. Hepatology. 2007;46(1):32-36.
Razavi H, Elkhoury AC, Elbasha E, et al. Chronic Hepatitis C Virus (HVC) Disease Burden and Cost in the United States. Hepatology. 2013;57(6):2164-2170.
Konstantinou DD, M. The Spectrum of HBV/HCV Coinfection: Epidemiology, Clinical Characteristics, Viral Interactions and Management. Annals of Gastroenterology. 2015;28(2):160-172.
HCVGuidlines.org. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. 2020; https://www.hcvguidlines.org.
